Klaviyo (KVYO) Co-CEO Bialecki Reports 10b5-1 Stock Sales
Rhea-AI Filing Summary
Klaviyo, Inc. insider activity: Co-Chief Executive Officer and director Andrew Bialecki reported preset stock sales executed under a Rule 10b5-1 trading plan adopted on May 20, 2025. On January 6, 2026, he converted 137,504 shares of Series B Common Stock into Series A Common Stock and sold 135,122 Series A shares at a weighted average price of $28.92 per share and 2,382 shares at a weighted average price of $28.52 per share. On January 7, 2026, he converted a further 16,649 Series B shares into Series A and sold all 16,649 Series A shares at a weighted average price of $30.01 per share. Each Series B share is convertible into one Series A share and has no expiration date. Following these transactions, he reports 69,414,736 Series B shares held directly, with additional Series B shares held indirectly through family trusts and by his spouse, subject to customary beneficial ownership disclaimers.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series B Common Stock | 16,649 | $0.00 | -- |
| Conversion | Series A Common Stock | 16,649 | $0.00 | -- |
| Sale | Series A Common Stock | 16,649 | $30.01 | $500K |
| Conversion | Series B Common Stock | 137,504 | $0.00 | -- |
| Conversion | Series A Common Stock | 137,504 | $0.00 | -- |
| Sale | Series A Common Stock | 135,122 | $28.92 | $3.91M |
| Sale | Series A Common Stock | 2,382 | $28.52 | $68K |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
| holding | Series B Common Stock | -- | -- | -- |
Footnotes (1)
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025. Each share of the Issuer's Series B Common Stock, par value $0.001 per share ("Series B Common Stock"), is convertible at any time at the option of the holder into one share of the Issuer's Series A Common Stock, par value $0.001 per share ("Series A Common Stock"), and will automatically convert into one share of Series A Common Stock upon the occurrence of certain events as set forth in the Issuer's certificate of incorporation. The Series B Common Stock has no expiration date. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.545 to $29.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.42 to $28.54 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.06 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Shares held by the Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023, of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Shares held by the Elizabeth L. Bialecki Irrevocable GST Trust of 2023, of which the Reporting Person serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose. Shares held by the Andrew P. Bialecki Irrevocable GST Trust of 2023, of which the Reporting Person's spouse serves as a trustee. The Reporting Person disclaims Section 16 beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.
FAQ
What insider transactions did Klaviyo (KVYO) Co-CEO Andrew Bialecki report?
Andrew Bialecki reported converting Series B Common Stock into Series A Common Stock and selling the resulting Series A shares on January 6 and 7, 2026, as disclosed in the Form 4.
Were Andrew Bialecki’s Klaviyo (KVYO) stock sales under a Rule 10b5-1 plan?
Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Andrew Bialecki on May 20, 2025.
What is the relationship between Klaviyo’s Series A and Series B Common Stock?
Each share of Series B Common Stock is convertible at any time into one share of Series A Common Stock and will automatically convert into one Series A share upon certain events. The Series B stock has no expiration date.
What trusts are associated with Andrew Bialecki’s indirect Klaviyo (KVYO) holdings?
Indirect holdings are reported through The Andrew P. Bialecki Grantor Retained Annuity Trust I of 2023, The Elizabeth L. Bialecki Irrevocable GST Trust of 2023, The Andrew P. Bialecki Irrevocable GST Trust of 2023, and shares held by his spouse, with standard Section 16 beneficial ownership disclaimers.